Navigation Links
A potent suppressor of endometrial cancer is revealed

Endometrial cancer is the most common cancer of the female reproductive tract, representing 6% of all cancers. There is currently no screening method or biomarker to indicate early presence of disease. "It is a very common malignancy that affects women of all ages" comments paper author Dr. Diego Castrillon. The cancer forms from the cells that grow along the inner lining of the uterus, which is called the endometrium, and usually it is diagnosed following patient reports of abnormal bleeding.

The normal endometrium is a dynamic place, providing a thick, highly vascularized environment ready to generate a placenta if it is implanted with an embryo. The dynamic and cyclic activity of the endometrium makes it very sensitive to signaling molecules. Early changes in a number of signaling proteins are known to contribute to endometrial cancer in some patients. A major research goal is to understand how signals create cancer cells and to identify places where intervention might shut down the signals that promote cancer cell survival and growth.

Researchers learn about cancer by creating genetic changes to signaling proteins in mice that reflect changes found in human cancer patients. Animal models are produced in this way to help understand how cancer cells form and progress. One challenge is to localize genetic changes to the environment of interest. In the case of endometrial cancer, researchers need to specifically modify only those cells that are in the endometrium, so that their data is not complicated by changes in other tissues.

In a new study published in Disease Models & Mechanisms (DMM), <>, scientists report a new genetic tool that can specifically alter gene expression in the endometrium. They use this approach to remove a signaling protein gene only in endometrial cells to determine its influence on endometrial cancer formation. They found that the genetic change induced a very rapidly progressing cancer in all mice that carried the mutation. The gene they deleted, called Lkb1, is mutated in many other types of human cancers, and it regulates pathways that are known to contribute to the formation of aggressive cancer cells.

Very few genetic changes act alone to induce cancer. Most cancer cells result from multiple mutations. However, all mice deficient for just Lkb1, exhibited cancerous changes throughout their entire endometrium. "In most mouse cancer models, one creates a tumor prone condition. But additional mutations are usually required for a cell to develop a cancer" says Dr. Castrillon, "What is surprising about the Lkb1 model, is that their entire endometrium becomes malignant. It happens very early and rapidly."

The rapid development of cancer in mice without Lkb1 suggests that this gene or the molecules that its product regulates may be valuable targets for future therapy. The authors show that treating the mice with a drug that blocks a downstream target of the Lkb1 product kills tumor cells, leading to tumor shrinkage and dramatic recovery of the mice. "It is likely that this pathway is very important. We believe that Lkb1 mutations or mutations in other steps in this pathway represent some type of metabolic abnormality that we could take advantage of [for therapeutic intervention]" says Dr. Castrillon.


Contact: Kristy Kain
The Company of Biologists

Related biology news :

1. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
2. Neuronal conduction of excitation without action potentials based on ceramide production
3. To maximize biofuel potential, researchers look for sorghums sweet spot
4. Joslin researchers uncover potential role of leptin in diabetes
5. Chemistry turns killer gas into potential cure
6. Researchers examine worlds potential to produce biodiesel
7. New inhibitor has potential as cancer drug
8. Potential new therapeutic molecular target to fight cancer
9. WCS study finds potential to double tiger numbers in South Asia
10. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
11. Great potential to improve collection, recycling of Europes electronic waste, says UN report
Post Your Comments:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology: